Михаил Владимирович Благосклонный
Blagosklonny, Mikhail V.
VIAF ID: 53502819 (Personal)
Permalink: http://viaf.org/viaf/53502819
Preferred Forms
-
- 100 1 _ ‡a Blagosklonny, Mikhail V.
- 100 1 _ ‡a Blagosklonny, Mikhail V.
- 100 1 _ ‡a Blagosklonny, Mikhail V.
- 100 0 _ ‡a Михаил Владимирович Благосклонный
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Cell cycle checkpoints and cancer, c2001: | |
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 | |
The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel. | |
p53 is associated with cellular microtubules and is transported to the nucleus by dynein | |
Paclitaxel-induced FasL-independent apoptosis and slow (non-apoptotic) cell death. | |
Paclitaxel induces primary and postmitotic G1 arrest in human arterial smooth muscle cells. | |
Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. | |
Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death? | |
Paradoxes of senolytics | |
Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection | |
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms | |
Phosphorylation of paxillin tyrosines 31 and 118 controls polarization and motility of lymphoid cells and is PMA-sensitive | |
The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors | |
Prevention of age-related macular degeneration-like retinopathy by rapamycin in rats. | |
Progeria, rapamycin and normal aging: recent breakthrough | |
Program-like aging and mitochondria: instead of random damage by free radicals | |
Prolonged mitosis versus tetraploid checkpoint: how p53 measures the duration of mitosis. | |
Prospective strategies to enforce selectively cell death in cancer cells | |
Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1) | |
Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells. | |
Proteasome-dependent regulation of p21WAF1/CIP1 expression | |
Pseudo-DNA damage response in senescent cells | |
The purpose of the HIF-1/PHD feedback loop: to limit mTOR-induced HIF-1α. | |
Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential | |
Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance | |
Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. | |
Rapalogs in cancer prevention: anti-aging or anticancer? | |
Rapamycin and quasi-programmed aging: four years later | |
Rapamycin decelerates cellular senescence | |
Rapamycin extends life- and health span because it slows aging | |
Rapamycin extends maximal lifespan in cancer-prone mice | |
Rapamycin for longevity: opinion article | |
Rapamycin for the aging skin | |
Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. | |
Rapamycin-induced glucose intolerance: hunger or starvation diabetes. | |
Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium | |
Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats | |
Re: Role of the heat shock response and molecular chaperones in oncogenesis and cell death. | |
Regulation of actin cytoskeleton in lymphocytes: PKC-delta disrupts IL-3-induced membrane ruffles downstream of Rac1. | |
Regulation of BRCA1 by protein degradation | |
The regulation of hypoxic genes by calcium involves c-Jun/AP-1, which cooperates with hypoxia-inducible factor 1 in response to hypoxia | |
Rejuvenating immunity: "anti-aging drug today" eight years later | |
Research by retrieving experiments | |
Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines | |
The restriction point of the cell cycle | |
Resveratrol potentiates rapamycin to prevent hyperinsulinemia and obesity in male mice on high fat diet | |
Revisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program | |
The role of Bcl-2 protein and autocrine growth factors in a human follicular lymphoma-derived B cell line. | |
S6K in geroconversion | |
Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel | |
Sensitive and simple bioassay for human tumour necrosis factor-alpha | |
Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs | |
Spotlight on apoptosis. Introduction | |
Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha | |
STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'. | |
Strategies of Protection of Normal Cells During Chemo- and Radio-Therapy Based on Modulation of Cell Cycle and Apoptotic Pathways | |
Suppression of cancer cell growth by adenovirus expressing p21(WAF1/CIP1) deficient in PCNA interaction | |
Suppression of replicative senescence by rapamycin in rodent embryonic cells | |
Target for cancer therapy: proliferating cells or stem cells | |
Targeting cancer cells by exploiting their resistance | |
Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway | |
Teratogens as anti-cancer drugs | |
Tissue-selective therapy of cancer | |
TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists | |
TOR-driven aging: speeding car without brakes | |
Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells | |
Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion | |
Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression? | |
UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response | |
Unwinding the loop of Bcl-2 phosphorylation | |
Validation of anti-aging drugs by treating age-related diseases | |
Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet | |
While reinforcing cell cycle arrest, rapamycin and Torins suppress senescence in UVA-irradiated fibroblasts. | |
Why human lifespan is rapidly increasing: solving "longevity riddle" with "revealed-slow-aging" hypothesis | |
Why Iressa failed: toward novel use of kinase inhibitors (outlook). | |
Why men age faster but reproduce longer than women: mTOR and evolutionary perspectives | |
Why the disposable soma theory cannot explain why women live longer and why we age. | |
Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance | |
Wild-type p53 is not sufficient for serum starvation-induced apoptosis in cancer cells but accelerates apoptosis in sensitive cells | |
Wild-type p53 marginally induces endogenous MDR-1 mRNA without causing a measurable drug resistance in human cancer cells | |
Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells | |
Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression |